JP2024531409A5 - - Google Patents
Info
- Publication number
- JP2024531409A5 JP2024531409A5 JP2024510434A JP2024510434A JP2024531409A5 JP 2024531409 A5 JP2024531409 A5 JP 2024531409A5 JP 2024510434 A JP2024510434 A JP 2024510434A JP 2024510434 A JP2024510434 A JP 2024510434A JP 2024531409 A5 JP2024531409 A5 JP 2024531409A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021113913 | 2021-08-20 | ||
| CNPCT/CN2021/113913 | 2021-08-20 | ||
| PCT/CN2022/113739 WO2023020621A1 (en) | 2021-08-20 | 2022-08-19 | Anti-ccr8 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531409A JP2024531409A (ja) | 2024-08-29 |
| JP2024531409A5 true JP2024531409A5 (https=) | 2025-08-26 |
Family
ID=85239303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510434A Pending JP2024531409A (ja) | 2021-08-20 | 2022-08-19 | 抗ｃｃｒ８抗体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250019451A1 (https=) |
| EP (1) | EP4388009A4 (https=) |
| JP (1) | JP2024531409A (https=) |
| KR (1) | KR20240046533A (https=) |
| CN (1) | CN118176210A (https=) |
| AU (1) | AU2022331786A1 (https=) |
| CA (1) | CA3225986A1 (https=) |
| IL (1) | IL310938A (https=) |
| MX (1) | MX2024002238A (https=) |
| WO (1) | WO2023020621A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2024040216A2 (en) | 2022-08-19 | 2024-02-22 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
| JP2025534340A (ja) * | 2022-10-02 | 2025-10-15 | アールイーエムディー バイオセラピューティクス，インコーポレイテッド | Ｃ－ｃケモカイン受容体タイプ８（ｃｃｒ８）アンタゴニスト抗体 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| WO2024255753A1 (zh) * | 2023-06-12 | 2024-12-19 | 南京蓬勃生物科技有限公司 | 结合人ccr8的抗体及其用途 |
| WO2025011439A1 (zh) * | 2023-07-07 | 2025-01-16 | 齐鲁制药有限公司 | 一种抗人ccr8的单克隆抗体药物制剂及其用途 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| CN119371535B (zh) * | 2024-09-20 | 2025-07-11 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| CN119841954B (zh) * | 2025-03-12 | 2025-11-04 | 上海百英生物科技股份有限公司 | 一种抗人ccr8单克隆抗体及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| CA3160204A1 (en) * | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
-
2022
- 2022-08-19 KR KR1020247007534A patent/KR20240046533A/ko active Pending
- 2022-08-19 CA CA3225986A patent/CA3225986A1/en active Pending
- 2022-08-19 AU AU2022331786A patent/AU2022331786A1/en active Pending
- 2022-08-19 JP JP2024510434A patent/JP2024531409A/ja active Pending
- 2022-08-19 MX MX2024002238A patent/MX2024002238A/es unknown
- 2022-08-19 WO PCT/CN2022/113739 patent/WO2023020621A1/en not_active Ceased
- 2022-08-19 CN CN202280069781.2A patent/CN118176210A/zh active Pending
- 2022-08-19 US US18/685,068 patent/US20250019451A1/en active Pending
- 2022-08-19 EP EP22857930.6A patent/EP4388009A4/en active Pending
- 2022-08-19 IL IL310938A patent/IL310938A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531409A5 (https=) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2021514664A5 (https=) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2021516057A5 (https=) | ||
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| JP2021526022A5 (https=) | ||
| JP2021528047A5 (https=) | ||
| JP2018526974A (ja) | Ｐｄｌ−１抗体、その医薬組成物及びその使用 | |
| JP2015155431A (ja) | Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物 | |
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| JP2023540526A5 (https=) | ||
| JP2025038088A5 (https=) | ||
| JP2021517459A5 (https=) | ||
| JP2022527173A5 (https=) | ||
| WO2024175093A1 (en) | Antibodies, antigen-binding fragments and methods of use | |
| JP2024540148A5 (https=) | ||
| JP2022532991A5 (https=) | ||
| JP2022526841A5 (https=) | ||
| JP2023525991A5 (https=) | ||
| JP2025511135A5 (https=) | ||
| CN117257934A (zh) | 药物组合物及其用途 | |
| CN114933655B (zh) | 抗cd123抗体及其应用 | |
| CN109053888B (zh) | 一种抗人csf-1r单克隆抗体及其用途 | |
| CN115960240A (zh) | 一种同时靶向人bcma和人cd3的双特异性抗体 |